| Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates |
Verve Therapeutics (VERV) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.59 per share a year ago. |
zacks.com |
2025-05-14 13:16:04 |
Czytaj oryginał (ang.) |
| Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results |
Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 |
globenewswire.com |
2025-05-14 11:00:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-05-02 20:05:00 |
Czytaj oryginał (ang.) |
| 1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street |
Equity markets have been volatile this year due to macroeconomic and geopolitical factors. Many of the world's largest corporations haven't escaped the sell-off, and it's hard to predict what's next. |
fool.com |
2025-04-29 11:53:00 |
Czytaj oryginał (ang.) |
| Why Verve Therapeutics Zoomed 40% Higher This Week |
Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics' (VERV 2.00%) big stock price leap this week. By the time the dust cleared, the biotech company's shares soared 40% higher over the period, according to data compiled by S&P Global Market Intelligence. |
fool.com |
2025-04-18 22:36:46 |
Czytaj oryginał (ang.) |
| Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy' |
VERV's VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102's development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV's pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly. |
seekingalpha.com |
2025-04-16 14:56:15 |
Czytaj oryginał (ang.) |
| VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study |
Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD. |
zacks.com |
2025-04-15 17:30:35 |
Czytaj oryginał (ang.) |
| Why Verve Therapeutics Is Skyrocketing Today |
Verve Therapeutics (VERV 22.57%) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. |
fool.com |
2025-04-15 16:43:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose |
Verve Therapeutics Inc VERV on Monday released initial data from the Heart-2 Phase 1b trial of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD), which requires reducing low-density lipoprotein cholesterol (LDL-C) levels in the blood. |
benzinga.com |
2025-04-14 15:34:54 |
Czytaj oryginał (ang.) |
| Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 |
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort |
globenewswire.com |
2025-04-14 11:00:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 |
BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VERVE-102 for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein cholesterol (LDL-C). VERVE-102 is the company's novel, in vivo, investigational base editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces disease-driving LDL-C. VERVE-102 is currently being tested in the Phase 1b Heart-2 clinical trial, which is designed to evaluate the safety and tolerability of VERVE-102 administration in adult patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD) who require additional lowering of LDL-C. |
globenewswire.com |
2025-04-11 11:00:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31, 2025, the company granted equity awards to three new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-04 20:05:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose |
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for VERVE-102 for the treatment of patients living with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). VERVE-102 is a novel, investigational in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood low-density lipoprotein cholesterol (LDL-C). |
globenewswire.com |
2025-03-24 09:00:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on February 28, 2025, the company granted equity awards to four new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-03 18:05:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates |
Verve Therapeutics (VERV) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.69 per share a year ago. |
zacks.com |
2025-02-27 11:25:35 |
Czytaj oryginał (ang.) |
| Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results |
Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025 |
globenewswire.com |
2025-02-27 09:00:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025, the company granted equity awards to eight new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-03 18:05:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm |
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Verve Therapeutics, Inc. (NASDAQ: VERV) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. |
prnewswire.com |
2025-01-31 13:11:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference |
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York. |
globenewswire.com |
2025-01-29 09:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accessnewswire.com |
2025-01-26 12:00:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last? |
Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-01-23 12:36:29 |
Czytaj oryginał (ang.) |
| Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accessnewswire.com |
2025-01-22 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accessnewswire.com |
2025-01-19 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Shareholders to Connect |
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accesswire.com |
2025-01-15 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accesswire.com |
2025-01-12 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accesswire.com |
2025-01-08 12:00:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accesswire.com |
2025-01-05 12:00:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31, 2024, the company granted equity awards to one new employee, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-01-03 18:05:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect |
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accesswire.com |
2025-01-02 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Stockholders to Connect |
NEW YORK CITY, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accesswire.com |
2024-12-29 12:00:00 |
Czytaj oryginał (ang.) |
| Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESSWIRE / December 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accesswire.com |
2024-12-26 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Stockholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accesswire.com |
2024-12-22 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accesswire.com |
2024-12-18 12:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out |
NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV. |
accesswire.com |
2024-12-15 12:00:00 |
Czytaj oryginał (ang.) |